Over 13 weeks, adults with type 2 diabetes using an automated insulin delivery (AID) system had a 0.6-percentage point ...

A survey conducted by the continuous glucose monitor maker Dexcom found that just over half of healthcare providers ranked ...

The overwhelming consensus amongst scientists is that there’s very little evidence to suggest that tracking your blood ...

Digital Health Leader's Innovation in Real-Time Sensor-Based AI Sets New Standards for Personalized Cardiometabolic Care The ...

The following is a summary of “Determinants of implementation of continuous glucose monitoring for patients with ...

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to ...

Dexcom (Nadsaq:DXCM) today announced new insulin delivery integrations and updates on enhanced continuous glucose monitors ...

The use of an automated insulin delivery (AID) system reduced A1c and hyperglycemia without increasing hypoglycemia in people ...

Dexcom (Nadsaq:DXCM) announced today that it launched a new multi-region report evaluating type 2 diabetes treatments.

A new petition highlights the urgent need for access to Continuous Glucose Monitoring for children with Type 1 Diabetes in ...

Tandem Diabetes Care, Inc. announced NEJM publication of positive results from Control-IQ+ AID technology pivotal trial in ...

Adults with insulin-treated type 2 diabetes had greater HbA1c reductions and larger improvement in time in range with use of ...